Article Text
Abstract
Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC development in patients with IPF remains unknown. This multicentre retrospective study evaluated 345 patients with IPF. The incidence and prevalence of LC were significantly lower in patients with IPF receiving antifibrotic therapy than those not receiving. Subsequently, LC-related mortality was significantly lower in patients with IPF receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC development in patients with IPF, which may be partly associated with its survival benefit.
- Idiopathic pulmonary fibrosis
- Lung Cancer
Statistics from Altmetric.com
Footnotes
Correction notice This article has been corrected since it was published Online First. The affiliation for authors MKo and HNak have been amended.
Contributors HNao and YS: conception and design, data collection, data analysis and interpretation, manuscript writing and final approval of the manuscript. KM: statistical analysis, data collection and data analysis. YA, MKo, HHa and KY: conception and design, data collection and data analysis. YI, HHo, MKa, KF, NE, TF, YN, NI and HNak: data collection, data analysis and supervision. TS: conception and design, manuscript writing and administrative support.
Funding This work was supported by a grant-in-aid for scientific research (19K17632 to YS) from the Japan Society for the Promotion of Science.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.